Ayr Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“Ayr” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator (“MSO”), is reporting financial results for the fourth quarter and full year ended December 31, 2022. Unless otherwise noted, all results are presented in U.S. dollars.
David Goubert, President & CEO of Ayr, said, “I’d like to thank our team for pulling together to deliver a strong fourth quarter, growing our adjusted EBITDA by 20% sequentially, and a second straight quarter of generating positive cash flow from operations. In the past few months, our team has begun the process of evaluating every aspect of our business with fresh eyes, conducting a thorough review of our markets, our people, and our processes, all in service seeking to maximize the financial health of our Company and better position Ayr as a retailer of choice and house of brands.”
“Throughout that process, we have implemented cost saving measures, stepped back from certain markets that didn’t align with our core business goals, and invested further into markets and activities that did meet those goals. By better prioritizing our time, our attention, and our capital, we find ourselves better positioned to capture growth opportunities in our existing and future footprint, which we anticipate will help us grow our cash flow profile, our revenue, and adjusted EBITDA margins consistently throughout 2023.”
Fourth Quarter Financial Summary ($ in millions, excl. margin items)
| Q4 2021 | Q3 2022 | Q4 2022 | % Change Q4/Q4 | % Change Q4/Q3 | |||||||||
| Revenue | $111.8 | $119.6 | $124.6 | 11.5 | % | 4.2 | % | ||||||
| Gross Profit | $51.2 | $49.5 | $55.1 | 7.6 | % | 11.3 | % | ||||||
| Adjusted Gross Profit1 | $63.3 | $62.9 | $70.5 | 11.3 | % | 12.1 | % | ||||||
| Operating Loss² | $(13.9 | ) | $(20.7 | ) | $(176.2 | ) | NA | NA | |||||
| Adjusted EBITDA1 | $26.1 | $21.7 | $26.0 | -0.5 | % | 20.1 | % | ||||||
| Adjusted EBITDA Margin1 | 23.4 | % | 18.1 | % | 20.9 | % | -250bps | 280bps |
Full Year 2022 Financial Summary ($ in millions, excl. margin items)
| FY 2021 | FY 2022 | % Change Y/Y | ||||||
| Revenue | $357.6 | $465.6 | 30.2 | % | ||||
| Gross Profit | $138.1 | $190.4 | 37.9 | % | ||||
| Adjusted Gross Profit1 | $207.3 | $248.5 | 19.9 | % | ||||
| Operating Loss² | $(56.0 | ) | $(243.0 | ) | NA | |||
| Adjusted EBITDA1 | $98.0 | $86.8 | -11.4 | % | ||||
| Adjusted EBITDA Margin1 | 27.4 | % | 18.6 | % | -880bps |
1Adjusted EBITDA, Adjusted Gross Profit and Adjusted EBITDA Margin are non-GAAP measures, and accordingly are not standardized measures and may not be comparable to similar measures used by other companies. See Definition and Reconciliation of Non-GAAP Measures below. For a reconciliation of Operating Loss to Adjusted EBITDA as well as Gross Profit to Adjusted Gross Profit, see the reconciliation table appended to this release.
2Based on the current market conditions, including the impact of price compression, the Company incurred a non-cash goodwill impairment charge of $149M, reducing the carrying value of goodwill across all reporting units.
Fourth Quarter and Recent Highlights
- Retail Updates
- Opened two new dispensaries in Florida during the fourth quarter and an additional two stores in the first quarter of 2023, bringing Ayr’s total footprint to 55 dispensaries across the state.
- Began adult-use sales alongside the Company’s established medical sales at Ayr’s Somerville, Massachusetts retail dispensary.
- Announced Ayr’s three retail locations in New Jersey, formerly known as Garden State Dispensary, are now operating under the AYR Dispensary brand.
- Brand/Product Updates
- Introduced HAZE live resin concentrates and vapes across the Company’s footprint in Florida and Nevada.
- Expanded Levia water-soluble tinctures to Ayr’s Florida retail menus.
- Announced plans to rebrand all of the Company’s Florida stores from Liberty Health Sciences to AYR Cannabis Dispensary this summer.
- Corporate Updates
- Announced mutual termination of Ayr’s proposed acquisition of the equity interests of Gentle Ventures, LLC d/b/a Dispensary 33, and certain of its affiliates that collectively own and operate two licensed retail dispensaries in Chicago, Illinois.
- Signed a definitive agreement to sell Blue Camo, LLC which comprises the Company’s Arizona assets, to AZ Goat, LLC, a group consisting primarily of the former owners of Blue Camo.
- Entered into an option to acquire two Ohio dispensary licenses from Daily Releaf, LLC and Heaven Wellness, LLC, to begin establishing a vertical integrated presence in the state.
Full Year 2022 Highlights
- Added 14 dispensaries across Ayr’s eight state footprint, bringing its total dispensary count to 80 stores.
- Launched adult-use retail sales in New Jersey and Massachusetts.
- Completed acquisitions of Cultivauna, LLC, the owner of Levia-branded cannabis infused beverages, and Herbal Remedies Dispensaries, LLC; Signed a management services agreement with Tahoe Hydroponics, LLC and NV Green, Inc.
- Won a provisional cultivation license in Connecticut alongside Ayr’s operating partner, which will also provide Ayr with two retail licenses in the state.
- Completed $114 million of real estate financing transactions at a blended cost of capital at closing of ~8.0% per annum.
- Completed construction of cultivation facilities in Massachusetts, New Jersey and Ohio.
Financing and Capital Structure
The Company deployed $3.6 million of capital expenditures in Q4 and ended the year with a cash balance of $80.6 million.
As of December 31, 2022, the Company had approximately 70.9 million fully diluted shares outstanding based on a treasury method calculation as of that date.i
Outlook
The Company anticipates its financial results in the first quarter of 2023 to be consistent with industry trends, expecting revenue and adjusted EBITDA in Q1 2023 to be in-line with Q4 2022. Ayr expects to further ramp revenue, adjusted EBITDA and operating cash flow thereafter.
Conference Call
Ayr management will host a conference call, followed by a question-and-answer period.
Conference Call Date: Thursday, March 9, 2023
Time: 8:30 a.m. ET
Toll-free dial-in number: (800) 319-4610
International dial-in number: (604) 638-5340
Conference ID: 10021221
Please dial into the conference call 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact the Company’s investor relations team at ir@ayrwellness.com.
The conference will be broadcast live and available for replay here.
A telephonic replay of the conference call will also be available for one month beginning at 11:30 a.m. ET on Thursday, March 9, 2023.
Toll-free replay number: (855) 669-9658
International replay number: (412) 317-0088
Replay ID: 9867
Financial Statements
Certain financial information reported in this news release is extracted from Ayr’s Consolidated Financial Statements and MD&A for years December 31, 2022 and 2021. Ayr files its financial statements and MD&A on SEDAR and with the SEC. All financial information contained in this news release is qualified in its entirety by reference to such financial statements and MD&A.
